Sandoz confirms European Commission nod of Pyzchiva
Basel: Sandoz has announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab) developed and registered by Samsung Bioepis. Pyzchiva is a key biosimilar value driver for the company over the mid-term and this approval is a major step in advancing Sandoz growth strategy. Pyzchiva is approved as a biologic therapy within […]
